BEAM - Beam Therapeutics' Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy | Benzinga
Beam Therapeutics Inc (NASDAQ: BEAM) announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy.
BEAM-201 is being evaluated in a Phase 1/2 study for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL).
William Blair views the update favorably, highlighting that this is the inaugural patient to undergo treatment with a Beam therapeutic candidate.
Furthermore, this patient is the first in the U.S. to receive a base-edited therapy, marking a significant milestone for the company and the entire gene editing sector.
Analysts Sami Corwin, ...